- Home
- ENLV vs KALA Comparison
ENLV vs KALA Comparison
Compare ENLV & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLV
- KALA
- Stock Information
- Founded
- ENLV 2005
- KALA 2009
- Country
- ENLV Israel
- KALA United States
- Employees
- ENLV N/A
- KALA N/A
- Industry
- ENLV Biotechnology: Pharmaceutical Preparations
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- ENLV Health Care
- KALA Health Care
- Exchange
- ENLV Nasdaq
- KALA Nasdaq
- Market Cap
- ENLV 26.6M
- KALA 26.2M
- IPO Year
- ENLV 1995
- KALA 2017
- Fundamental
- Price
- ENLV $1.06
- KALA $0.81
- Analyst Decision
- ENLV Strong Buy
- KALA Buy
- Analyst Count
- ENLV 2
- KALA 3
- Target Price
- ENLV $10.00
- KALA $31.50
- AVG Volume (30 Days)
- ENLV 180.4K
- KALA 3.0M
- Earning Date
- ENLV 11-28-2025
- KALA 11-11-2025
- Dividend Yield
- ENLV N/A
- KALA N/A
- EPS Growth
- ENLV N/A
- KALA N/A
- EPS
- ENLV N/A
- KALA N/A
- Revenue
- ENLV N/A
- KALA N/A
- Revenue This Year
- ENLV N/A
- KALA N/A
- Revenue Next Year
- ENLV N/A
- KALA N/A
- P/E Ratio
- ENLV N/A
- KALA N/A
- Revenue Growth
- ENLV N/A
- KALA N/A
- 52 Week Low
- ENLV $0.81
- KALA $0.77
- 52 Week High
- ENLV $2.10
- KALA $20.60
- Technical
- Relative Strength Index (RSI)
- ENLV 47.24
- KALA 26.18
- Support Level
- ENLV $1.04
- KALA $0.80
- Resistance Level
- ENLV $1.10
- KALA $1.52
- Average True Range (ATR)
- ENLV 0.05
- KALA 0.12
- MACD
- ENLV -0.00
- KALA 0.21
- Stochastic Oscillator
- ENLV 22.22
- KALA 3.05
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.